IBRX vs JBTM Comparison

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

JBT Marel Corp operates through two reportable segments: Protein Solutions and Prepared Food and Beverage Solutions. The Protein Solutions segment includes businesses that provide solutions for the initial stage processing and harvesting of animal proteins, mainly focusing on poultry, pork, fish, and beef. The Prepared Food and Beverage Solutions segment includes businesses that offer solutions predominantly for downstream value-added preparation, preservation, and packaging of foods and beverages into ready-to-eat or drink products. This segment will also include capabilities for pet food, dairy, bakery, pharmaceutical, nutraceutical, and warehouse automation end markets. The majority of its revenue is generated from the Prepared Food and Beverage Solutions segment.